Kalaris Therapeutics, Inc. Common Stock (KLRS)

• Market cap: $72.8M
• 1 day: -9.11%
• 5 days: -13.36%
• 1 month: 56.22%
• 3 months: 40.94%
• 6 months: -59.77%
• Year to date: -62.42%
• 1 year: -77.42%
• 5 years: -99.21%
• 10 years: -99.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

2.73% less ownership

Funds ownership: 74.19% [Q1] → 71.47% (-2.73%) [Q2]

3% less funds holding

Funds holding: 32 [Q1] → 31 (-1) [Q2]

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

68% less capital invested

Capital invested by funds: $111M [Q1] → $35.7M (-$75.7M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $23
• Avg. target: $23
• High target: $23

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Raymond James Chris Raymond

$23

Strong Buy Initiated

3 Sep 2025